Developer docs
API playgroundTry for free, no card

Search company profiles

Outcomes4Me

Full company profile

uuid000054g

Namestring
Outcomes4Me
Legal namestring
Outcomes4Me Inc.
Websiteurl
outcomes4me.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Outcomes4Me Inc. is a Boston-based digital health company founded in 2017 that operates an AI-driven direct-to-patient platform designed to help cancer patients navigate their care from diagnosis through every stage of treatment. The platform integrates NCCN Clinical Practice Guidelines in Oncology with genomic insights, medication and symptom tracking, clinical trial matching, genetic testing access (via Invitae NGS partnership), and peer community support, using AI to translate clinical information into personalized patient-facing guidance. The technology stack includes patented recommendation, knowledge retrieval, predictive analytics, and process automation capabilities, augmented by acquisitions of EHR-integrated patient data (Geno.Me — Epic, Cerner, Meditech), an AI clinical trial matching engine (Realyze Intelligence), and a certified medical device digital therapeutic (MIKA Health).

The company operates a dual-sided business model: the patient-facing mobile and web application is offered free of charge and serves over 400,000 cancer patients across breast, lung, prostate, colorectal, bladder, ovarian and other cancer types. Revenue is generated on the B2B side through enterprise partnerships with pharmaceutical and life sciences companies — Outcomes4Me reports that seven of the top ten global cancer pharmaceutical companies are customers. B2B revenue streams include subscription-based content and precision marketing, clinical trial recruitment (with 5-10x pre-screen efficiency claimed), and real-world data access leveraging proprietary multimodal patient-level datasets enriched at the drug level. The company has also established research and clinical collaborations with academic cancer centers including Johns Hopkins, Massachusetts General Hospital, Vanderbilt, and UPMC Hillman Cancer Center, and counts Labcorp, NBCUniversal, Pfizer, Foundation Medicine, and CURE among its enterprise partners.

Since commercial launch in 2022, Outcomes4Me has executed a $12M Series A (May 2021), a $21M funding round (May 2025) led by London-based Salica Investments with Labcorp Venture Fund participation, and three acquisitions: MIKA Health (June 2025), Geno.Me (May 2026), and Realyze Intelligence (May 2026). The company is venture-backed with $38M in total capital raised, operates with 11-50 employees, and is led by founder and CEO Maya R. Said, Sc.D., formerly of Novartis.

Short descriptiontext

Outcomes4Me operates an AI-driven platform for cancer patients, providing personalized treatment guidance, clinical trial matching, genomic insights, and symptom tracking. It monetizes through B2B partnerships with pharmaceutical companies and health systems, serving over 400,000 patients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology patient empowerment, AI cancer care platform, clinical trial matching, real-world evidence data, digital therapeutics oncology
Industry4 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAGACAD
Clinical Trial Patient Recruitment & Retention
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Digital Health - Oncology Patient Empowerment Platform
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Life Sciences Partnerships
TypeSubscription Recurring
Description

Revenue from pharmaceutical and life sciences companies who partner with Outcomes4Me for patient engagement, content marketing, clinical trial recruitment, and real-world data access. Seven out of the top 10 global cancer pharmaceutical companies are customers.

outcomes4me.com
2Content & Precision Marketing
TypeSubscription Recurring
Description

Lead generation and content integration services for pharmaceutical partners, including awareness campaigns, conversion through custom events, and patient education content that seamlessly integrates real-time information into patient interactions.

outcomes4me.com
3Clinical Trial Recruitment
TypeProfessional Services
Description

Pre-screening and recruitment services for clinical trials, providing qualified pre-screened patients with complete medical records and eligibility packets to pharmaceutical and research partners.

outcomes4me.com
4Real-world Data
TypeData Monetisation
Description

Access to regulatory-grade outcomes data and real-world evidence capabilities for pharmaceutical and research partners, leveraging proprietary patient-level datasets.

outcomes4me.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details2 tiers
1Free patient app
ModelFreemiumBilling cadenceOthers
Notes

The AI-driven cancer care platform is free for patients, providing personalized treatment plans, symptom tracking, clinical trial matching, and community support at no cost.

outcomes4me.com
2Life Sciences Enterprise
ModelSubscriptionBilling cadenceAnnual
Notes

Partnership arrangements with pharmaceutical companies for content marketing, clinical trial recruitment, and real-world data access are likely custom enterprise agreements.

outcomes4me.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

Outcomes4Me operates an AI-driven direct-to-patient platform that empowers cancer patients with personalized treatment guidance, integrating NCCN Clinical Practice Guidelines, genomic insights, clinical trial matching, symptom/medication tracking, and peer community support. The company also generates B2B revenue by partnering with pharmaceutical companies on content marketing, clinical trial recruitment, and real-world data access, with seven of the top 10 global cancer pharmaceutical companies as customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Highest quality application among over 3,000 applications for adults with cancer worldwide (peer-reviewed study in Current Oncology)
+3 more records
Product overview1 text field

Outcomes4Me is a single, unified AI-driven direct-to-patient platform for cancer care empowerment, combining core platform capabilities with acquired technologies. The core Outcomes4Me Platform integrates clinical guidelines, genomics, clinical trial matching, and symptom tracking. Acquired brands include Geno.Me (EHR-integrated patient data access), Realyze Intelligence (AI-powered trial matching), and MIKA Health (certified digital therapeutics app). Sub-products include genetic testing partnerships with Invitae and Foundation Medicine, dedicated clinical trial matching tools, and patient peer communities. The platform supports over 400,000 cancer patients across multiple cancer types including breast, prostate, lung, colorectal, bladder, and others.

Product and service7 records
1Outcomes4Me Platform
CategoryCore Platform - Consumer App
Description

AI-driven direct-to-patient cancer care empowerment platform that integrates NCCN Clinical Practice Guidelines in Oncology, genomic insights, symptom and medication tracking, clinical trial matching, and peer community support to give cancer patients personalized, evidence-based guidance from diagnosis through every stage of care. Free to patients; supports over 400,000 cancer patients across multiple cancer types.

2Clinical Trial Matching
CategorySub-product - Patient Service & Enterprise Offering
Description

AI-driven clinical trial matching service that connects cancer patients with relevant research opportunities based on diagnosis, biomarkers, and treatment history. Enables 5-10X pre-screen efficiency for clinical trial recruitment offered to pharmaceutical partners.

3Genetic Testing Partnership Services
CategorySub-product - Patient Service
Description

Partnership-driven genetic testing service providing clinical-grade, next-generation sequencing-based testing analyzing more than 80 genes for cancer patients and family members, plus research collaborations on genomic testing awareness with Foundation Medicine.

4Patient Communities
CategorySub-product - Patient Community
Description

Peer support communities connecting patients with similar cancer types, treatment journeys, biomarkers, and lived experiences, including 100+ cancer-type-specific communities with over 700,000 total members.

5Realyze Intelligence
CategoryAcquired Technology - Clinical Trial Matching
Description

AI-powered clinical trial matching platform that extracts oncology data from medical records and automatically identifies clinical trial matches for patients; originally developed at UPMC.

6Geno.Me
CategoryAcquired Technology - Patient Data Platform
Description

Patient-controlled health data access platform with integrations to Epic, Cerner, and Meditech electronic health record systems, enabling patients to aggregate and share medical records through Outcomes4Me.

7MIKA Health
CategoryAcquired Product - Digital Therapeutics
Description

Certified medical device app clinically proven to help cancer patients cope with their condition through digital therapeutics and personalized recommendations; acquired from Berlin-based Fosanis GmbH.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Strategic partnership with UPMC Hillman Cancer Center including appointment of CIO Scot Stevens as Strategic Advisor. Realyze Intelligence technology was initially developed at UPMC.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership with Invitae providing direct access to genetic testing for cancer patients. Invitae provides clinical-grade next-generation sequencing (NGS) genetic testing analyzing more than 80 genes for cancer patients and family members.

Strategic tierStrategicTypeTechnology or Integration
Description

Research partnership studying genomic testing awareness and utilization in breast cancer patients. Outcomes4Me collaborated with Foundation Medicine on a study of over 200 breast cancer patients demonstrating discrepancy between willingness to get genomic testing and extent to which it is being offered.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

World-class collaboration with Johns Hopkins University as part of the oncology care provider network supporting patient care and improving patient outcomes.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

World-class collaboration with MGH as part of the oncology care provider network supporting patient care and improving patient outcomes.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

World-class collaboration with Vanderbilt as part of the oncology care provider network supporting patient care and improving patient outcomes.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Partnership with National Comprehensive Cancer Network (NCCN) enabling integration with NCCN Clinical Practice Guidelines in Oncology, the first digital platform to do so.

Strategic tierStrategicTypeTechnology or Integration
Description

Collaboration with Wolters Kluwer for evidence-based clinical information supporting the oncology care provider network.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Partnership with CURE for the ASCO 2025 Breast Cancer Briefing Room, providing exclusive coverage of ASCO abstracts, sessions and key data specific to breast cancer.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Founder and CEO Maya Said featured on Pfizer's Science Will Win podcast discussing AI in cancer care and the pace of science.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Cancer care partnership with NBCUniversal as part of broader consumer engagement initiatives.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Acquired from Fosanis GmbH (Germany) in June 2025. MIKA Health is a certified medical device clinically proven to help cancer patients cope with their disease, expanding Outcomes4Me's European presence.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven clinical trial matching and patient recruitment platform for oncology, closely comparable to Outcomes4Me's trial matching and pharma services offering.

2Carevive
TypeDirect peer
Description

Oncology patient-reported outcomes, symptom management, and care planning platform serving both providers and pharma, comparable to Outcomes4Me's symptom tracking and pharma RWD business.

TypeDirect peer
Description

Patient engagement platform for oncology practices that combines symptom tracking, patient education, and clinical trial matching, directly comparable to Outcomes4Me's direct-to-patient platform.

4Tempus
TypeBroad incumbent
Description

Precision medicine and AI platform combining genomics, clinical data, and trial matching for oncology. Larger and broader in scope than Outcomes4Me but competes in adjacent precision oncology decision support.

TypeBroad incumbent
Description

Oncology EHR and real-world data provider for community oncology practices and pharma research, acquired by Roche. Comparable in real-world data and oncology clinical trial enablement, with much broader scale.

TypeEmerging player
Description

Precision oncology platform focused on cancer risk assessment, genetic testing, and clinical decision support for providers, partially overlapping with Outcomes4Me's genomic integration and decision support capabilities.

TypeEmerging player
Description

Digital cancer care platform providing personalized guidance, care navigation, and peer support for cancer patients, closely comparable to Outcomes4Me's patient-facing consumer model.

TypeEmerging player
Description

Specialized digital care platform for oncology patients focused on financial assistance and care navigation, with partial overlap to Outcomes4Me's patient empowerment value proposition.

TypeBroad incumbent
Description

Dominant EHR vendor whose MyChart patient portal is integrated via Geno.Me, and which could either partner with or compete against Outcomes4Me in cancer patient digital engagement.

TypeOthers
Description

Genomic profiling and molecular information partner of Outcomes4Me; comparable in oncology precision and clinical research support, and a current collaboration partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Outcomes4Me

Digital Health - Oncology Patient Empowerment Platformoutcomes4me.com

Outcomes4Me operates an AI-driven platform for cancer patients, providing personalized treatment guidance, clinical trial matching, genomic insights, and symptom tracking. It monetizes through B2B partnerships with pharmaceutical companies and health systems, serving over 400,000 patients globally.

What Outcomes4Me does

Outcomes4Me Inc. is a Boston-based digital health company founded in 2017 that operates an AI-driven direct-to-patient platform designed to help cancer patients navigate their care from diagnosis through every stage of treatment. The platform integrates NCCN Clinical Practice Guidelines in Oncology with genomic insights, medication and symptom tracking, clinical trial matching, genetic testing access (via Invitae NGS partnership), and peer community support, using AI to translate clinical information into personalized patient-facing guidance. The technology stack includes patented recommendation, knowledge retrieval, predictive analytics, and process automation capabilities, augmented by acquisitions of EHR-integrated patient data (Geno.Me — Epic, Cerner, Meditech), an AI clinical trial matching engine (Realyze Intelligence), and a certified medical device digital therapeutic (MIKA Health).

The company operates a dual-sided business model: the patient-facing mobile and web application is offered free of charge and serves over 400,000 cancer patients across breast, lung, prostate, colorectal, bladder, ovarian and other cancer types. Revenue is generated on the B2B side through enterprise partnerships with pharmaceutical and life sciences companies — Outcomes4Me reports that seven of the top ten global cancer pharmaceutical companies are customers. B2B revenue streams include subscription-based content and precision marketing, clinical trial recruitment (with 5-10x pre-screen efficiency claimed), and real-world data access leveraging proprietary multimodal patient-level datasets enriched at the drug level. The company has also established research and clinical collaborations with academic cancer centers including Johns Hopkins, Massachusetts General Hospital, Vanderbilt, and UPMC Hillman Cancer Center, and counts Labcorp, NBCUniversal, Pfizer, Foundation Medicine, and CURE among its enterprise partners.

Since commercial launch in 2022, Outcomes4Me has executed a $12M Series A (May 2021), a $21M funding round (May 2025) led by London-based Salica Investments with Labcorp Venture Fund participation, and three acquisitions: MIKA Health (June 2025), Geno.Me (May 2026), and Realyze Intelligence (May 2026). The company is venture-backed with $38M in total capital raised, operates with 11-50 employees, and is led by founder and CEO Maya R. Said, Sc.D., formerly of Novartis.

Outcomes4Me firmographics

Firmographics
Name
Outcomes4Me
Legal name
Outcomes4Me Inc.
Website
https://outcomes4me.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Outcomes4Me operates an AI-driven platform for cancer patients, providing personalized treatment guidance, clinical trial matching, genomic insights, and symptom tracking. It monetizes through B2B partnerships with pharmaceutical companies and health systems, serving over 400,000 patients globally.
Ownership category
akta.pro rank

Outcomes4Me industry classification

Industry
Product category
Digital Health - Oncology Patient Empowerment Platform
NAICS
Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAGACAD
Clinical Trial Patient Recruitment & Retention
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)

Keywords

  • Oncology patient empowerment
  • AI cancer care platform
  • Clinical trial matching
  • Real-world evidence data
  • Digital therapeutics oncology

Where Outcomes4Me is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Outcomes4Me business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Life Sciences Partnerships: Revenue from pharmaceutical and life sciences companies who partner with Outcomes4Me for patient engagement, content marketing, clinical trial recruitment, and real-world data access. Seven out of the top 10 global cancer pharmaceutical companies are customers.
  2. Content & Precision Marketing: Lead generation and content integration services for pharmaceutical partners, including awareness campaigns, conversion through custom events, and patient education content that seamlessly integrates real-time information into patient interactions.
  3. Clinical Trial Recruitment: Pre-screening and recruitment services for clinical trials, providing qualified pre-screened patients with complete medical records and eligibility packets to pharmaceutical and research partners.
  4. Real-world Data: Access to regulatory-grade outcomes data and real-world evidence capabilities for pharmaceutical and research partners, leveraging proprietary patient-level datasets.

Pricing tiers

ModelBillingPrice
FreemiumOthersFree patient app
SubscriptionAnnualLife Sciences Enterprise

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Outcomes4Me product offering

Product offering

Core offering

Outcomes4Me operates an AI-driven direct-to-patient platform that empowers cancer patients with personalized treatment guidance, integrating NCCN Clinical Practice Guidelines, genomic insights, clinical trial matching, symptom/medication tracking, and peer community support. The company also generates B2B revenue by partnering with pharmaceutical companies on content marketing, clinical trial recruitment, and real-world data access, with seven of the top 10 global cancer pharmaceutical companies as customers.

Product overview

Outcomes4Me is a single, unified AI-driven direct-to-patient platform for cancer care empowerment, combining core platform capabilities with acquired technologies. The core Outcomes4Me Platform integrates clinical guidelines, genomics, clinical trial matching, and symptom tracking. Acquired brands include Geno.Me (EHR-integrated patient data access), Realyze Intelligence (AI-powered trial matching), and MIKA Health (certified digital therapeutics app). Sub-products include genetic testing partnerships with Invitae and Foundation Medicine, dedicated clinical trial matching tools, and patient peer communities. The platform supports over 400,000 cancer patients across multiple cancer types including breast, prostate, lung, colorectal, bladder, and others.

Differentiator

Problem solved

Functional benefit

Products and services

  • Outcomes4Me Platform AI-driven direct-to-patient cancer care empowerment platform that integrates NCCN Clinical Practice Guidelines in Oncology, genomic insights, symptom and medication tracking, clinical trial matching, and peer community support to give cancer patients personalized, evidence-based guidance from diagnosis through every stage of care. Free to patients; supports over 400,000 cancer patients across multiple cancer types.
  • Clinical Trial Matching AI-driven clinical trial matching service that connects cancer patients with relevant research opportunities based on diagnosis, biomarkers, and treatment history. Enables 5-10X pre-screen efficiency for clinical trial recruitment offered to pharmaceutical partners.
  • Genetic Testing Partnership Services Partnership-driven genetic testing service providing clinical-grade, next-generation sequencing-based testing analyzing more than 80 genes for cancer patients and family members, plus research collaborations on genomic testing awareness with Foundation Medicine.
  • Patient Communities Peer support communities connecting patients with similar cancer types, treatment journeys, biomarkers, and lived experiences, including 100+ cancer-type-specific communities with over 700,000 total members.
  • Realyze Intelligence AI-powered clinical trial matching platform that extracts oncology data from medical records and automatically identifies clinical trial matches for patients; originally developed at UPMC.
  • Geno.Me Patient-controlled health data access platform with integrations to Epic, Cerner, and Meditech electronic health record systems, enabling patients to aggregate and share medical records through Outcomes4Me.
  • MIKA Health Certified medical device app clinically proven to help cancer patients cope with their condition through digital therapeutics and personalized recommendations; acquired from Berlin-based Fosanis GmbH.

Quantifiable outcome

  • Highest quality application among over 3,000 applications for adults with cancer worldwide (peer-reviewed study in Current Oncology)
  • +3 more outcomes

Companies that use Outcomes4Me

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Outcomes4Me technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature6 records

Outcomes4Me partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core and strategic.

  • UPMC Hillman Cancer CenterflagshipStrategic or Co-development Partner · 21 May 2026Strategic partnership with UPMC Hillman Cancer Center including appointment of CIO Scot Stevens as Strategic Advisor. Realyze Intelligence technology was initially developed at UPMC.
  • InvitaecoreTechnology or IntegrationPartnership with Invitae providing direct access to genetic testing for cancer patients. Invitae provides clinical-grade next-generation sequencing (NGS) genetic testing analyzing more than 80 genes for cancer patients and family members.
  • Foundation Medicine Inc.strategicTechnology or IntegrationResearch partnership studying genomic testing awareness and utilization in breast cancer patients. Outcomes4Me collaborated with Foundation Medicine on a study of over 200 breast cancer patients demonstrating discrepancy between willingness to get genomic testing and extent to which it is being offered.
  • Johns Hopkins UniversityflagshipStrategic or Co-development PartnerWorld-class collaboration with Johns Hopkins University as part of the oncology care provider network supporting patient care and improving patient outcomes.
  • Massachusetts General HospitalflagshipStrategic or Co-development PartnerWorld-class collaboration with MGH as part of the oncology care provider network supporting patient care and improving patient outcomes.
  • VanderbiltflagshipStrategic or Co-development PartnerWorld-class collaboration with Vanderbilt as part of the oncology care provider network supporting patient care and improving patient outcomes.
  • NCCNflagshipStrategic or Co-development PartnerPartnership with National Comprehensive Cancer Network (NCCN) enabling integration with NCCN Clinical Practice Guidelines in Oncology, the first digital platform to do so.
  • Wolters KluwerstrategicTechnology or IntegrationCollaboration with Wolters Kluwer for evidence-based clinical information supporting the oncology care provider network.
  • CUREstrategicGTM or Marketing PartnerPartnership with CURE for the ASCO 2025 Breast Cancer Briefing Room, providing exclusive coverage of ASCO abstracts, sessions and key data specific to breast cancer.
  • PfizerstrategicGTM or Marketing PartnerFounder and CEO Maya Said featured on Pfizer's Science Will Win podcast discussing AI in cancer care and the pace of science.
  • NBCUniversalstrategicGTM or Marketing PartnerCancer care partnership with NBCUniversal as part of broader consumer engagement initiatives.
  • MIKA HealthcoreOEM/ Whitelabel/ Licensing PartnerAcquired from Fosanis GmbH (Germany) in June 2025. MIKA Health is a certified medical device clinically proven to help cancer patients cope with their disease, expanding Outcomes4Me's European presence.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Outcomes4Me competitors and assessment

Company assessment

Direct peers

  • Massive Bio: AI-driven clinical trial matching and patient recruitment platform for oncology, closely comparable to Outcomes4Me's trial matching and pharma services offering.
  • Carevive: Oncology patient-reported outcomes, symptom management, and care planning platform serving both providers and pharma, comparable to Outcomes4Me's symptom tracking and pharma RWD business.
  • Navigating Cancer: Patient engagement platform for oncology practices that combines symptom tracking, patient education, and clinical trial matching, directly comparable to Outcomes4Me's direct-to-patient platform.

Broad incumbents

  • Tempus: Precision medicine and AI platform combining genomics, clinical data, and trial matching for oncology. Larger and broader in scope than Outcomes4Me but competes in adjacent precision oncology decision support.
  • Flatiron Health: Oncology EHR and real-world data provider for community oncology practices and pharma research, acquired by Roche. Comparable in real-world data and oncology clinical trial enablement, with much broader scale.
  • Epic Systems (MyChart): Dominant EHR vendor whose MyChart patient portal is integrated via Geno.Me, and which could either partner with or compete against Outcomes4Me in cancer patient digital engagement.

Emerging players

  • CancerIQ: Precision oncology platform focused on cancer risk assessment, genetic testing, and clinical decision support for providers, partially overlapping with Outcomes4Me's genomic integration and decision support capabilities.
  • Jasper Health: Digital cancer care platform providing personalized guidance, care navigation, and peer support for cancer patients, closely comparable to Outcomes4Me's patient-facing consumer model.
  • VivorCare: Specialized digital care platform for oncology patients focused on financial assistance and care navigation, with partial overlap to Outcomes4Me's patient empowerment value proposition.

Others

  • Foundation Medicine: Genomic profiling and molecular information partner of Outcomes4Me; comparable in oncology precision and clinical research support, and a current collaboration partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Outcomes4Me social profiles

Digital presence

Outcomes4Me financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Outcomes4Me leadership team

Management profile

Number of profiles

Profiles10 records

Outcomes4Me subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Outcomes4Me funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Outcomes4Me M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Outcomes4Me

What does Outcomes4Me do?

Outcomes4Me operates an AI-driven direct-to-patient platform that empowers cancer patients with personalized treatment guidance, integrating NCCN Clinical Practice Guidelines, genomic insights, clinical trial matching, symptom/medication tracking, and peer community support. The company also generates B2B revenue by partnering with pharmaceutical companies on content marketing, clinical trial recruitment, and real-world data access, with seven of the top 10 global cancer pharmaceutical companies as customers.

Is Outcomes4Me a public or private company?

Outcomes4Me is a private company. It is classified as venture growth investor backed and is currently operating.

When was Outcomes4Me founded?

Outcomes4Me was founded in 2017. It employs 11 to 50 people.

Where is Outcomes4Me based?

Outcomes4Me is headquartered in Boston, United States, in the North America region.

How does Outcomes4Me make money?

Four revenue lines are on record. Life Sciences Partnerships are the primary driver. The others are content & Precision Marketing, clinical Trial Recruitment and real-world Data.

Who are Outcomes4Me's main competitors?

Direct peers on record are Massive Bio, Carevive and Navigating Cancer. Broad incumbents are Tempus, Flatiron Health and Epic Systems (MyChart). Emerging players are CancerIQ, Jasper Health and VivorCare. Foundation Medicine is listed as an others.

Does Outcomes4Me have an API?

No public API is recorded for Outcomes4Me.

What industry is Outcomes4Me in?

Outcomes4Me's product category is Digital Health - Oncology Patient Empowerment Platform. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its NAICS code is 5417 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVeteran Health Tech Leader Jim Longley Joins the Outcomes4Me Executive Team to Accelerate Growth and Support Mission of Empowering Patients with CancerJim Longley, previously SVP of AI Partnerships at OpenEvidence, joined Outcomes4Me as Chief Revenue Officer to lead its commercial team. The company, which supports over 400,000 cancer patients, has seen 395% three-year growth and was named to the Inc. 5000 list. Longley aims to expand life sciences collaborations.MorningstarVeteran Health Tech Leader Jim Longley Joins the Outcomes4Me Executive Team to Accelerate Growth and Support Mission of Empowering Patients with CancerJim Longley, previously SVP of AI Partnerships at OpenEvidence, joined Outcomes4Me as Chief Revenue Officer to lead its commercial team. The company, which supports over 400,000 cancer patients, has seen 395% three-year growth and was named to the Inc. 5000 list.Pulse 2.0Outcomes4Me: AI-Driven Cancer Care Company Acquires Geno.Me And Realyze Intelligence To Expand Clinical Trial AccessOutcomes4Me announced the acquisitions of Geno.Me and Realyze Intelligence to strengthen its AI-powered cancer care and clinical trial matching platform. The combined technologies integrate patient medical record access, AI-driven data abstraction, and rapid clinical trial matching to help cancer patients access evidence-based treatments and research opportunities faster. The acquisitions are expected to expand Outcomes4Me's ability to support more than 400,000 cancer patients while enhancing its real-world evidence capabilities for pharmaceutical and research partners.citybizOutcomes4Me Acquires Geno.Me and Realyze Intelligence to Expand AI Cancer Care PlatformBoston-based Outcomes4Me has acquired healthcare technology platforms Geno.Me and Realyze Intelligence to expand its AI-driven cancer care and clinical trial matching capabilities, strengthening its position in the growing market for digital oncology tools. Geno.Me provides patient-controlled health data access with integrations to Epic, Cerner, and Meditech electronic health record systems, while Realyze Intelligence uses AI to extract oncology data from medical records and identify clinical trial matches. The acquisitions, combined with the addition of UPMC Hillman Cancer Center CIO Scot Stevens as strategic advisor, will enable Outcomes4Me to enhance personalized treatment guidance and accelerate connections between patients and oncology research programs for its existing base of over 400,000 cancer patients.PR NewswireOutcomes4Me Acquires Geno.Me and Realyze Intelligence, Names UPMC Hillman Cancer Center CIO as Strategic Advisor, to Expedite AI-driven Cancer Care and Clinical Trial AccessOutcomes4Me Inc. has completed acquisitions of Geno.Me, a patient data platform integrated with major EHR systems, and Realyze Intelligence, an AI-powered clinical trial matching platform initially developed at UPMC. The company also appointed Scot Stevens, CIO of UPMC Hillman Cancer Center, as Strategic Advisor. These acquisitions will integrate Realyze's trial matching technology and Geno.Me's data access capabilities into Outcomes4Me's existing direct-to-patient cancer care platform, which already supports over 400,000 cancer patients.Outcomes4MeOutcomes4Me Acquires Geno.Me and Realyze Intelligence, Names UPMC Hillman Cancer Center CIO as Strategic Advisor, to Expedite AI-driven Cancer Care and Clinical Trial AccessOutcomes4Me completed acquisitions of Geno.Me and Realyze Intelligence, adding AI-driven clinical trial matching and patient data access. The company also appointed Scot Stevens, CIO of UPMC Hillman Cancer Center, as strategic advisor. The combined platform aims to expand patient access to clinical trials and personalized care.BizTimesMilwaukee-based biotech startup Geno.Me acquired by Boston companyMilwaukee-based biotech startup Geno.Me has been acquired by Boston-based Outcomes4Me for an undisclosed price. The transaction was confirmed via an email sent to Geno.Me users as of February 2026. This acquisition represents a strategic consolidation within the biotech sector.PR NewswireOUTCOMES4ME NAMED TO TIME'S LIST OF THE BEST INVENTIONS OF 2025Outcomes4Me announced it has been named to TIME's Best Inventions of 2025 list, recognizing its AI-driven patient empowerment platform for cancer patients that integrates clinical guidelines, genomics, clinical trial matching, and symptom management. The platform now supports over 400,000 cancer patients globally and works with eight of the top 10 global cancer pharmaceutical companies. The company also recently acquired Europe's Mika app, making it the largest cancer platform worldwide, and debuted on the Inc. 5000 list of fastest-growing private companies.PR NewswireOutcomes4Me Acquires Germany's Mika Health App to Accelerate AI-Driven Patient Empowerment GloballyOutcomes4Me Germany acquired Mika Health app assets from Fosanis GmbH, adding Mika's AI-driven emotional support to its platform. Mika has served over 100,000 cancer patients and is an MDR IIa-certified medical device. Outcomes4Me will exhibit at HLTH Europe in Amsterdam.VC News DailyOutcomes4Me Secures $21M Funding RoundOutcomes4Me, a Boston-based AI-driven patient empowerment platform for cancer care, announced the close of a $21 million funding round with new investor Salica Investments joining existing investors Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD. The round brings the company's total capital raised to date to $38 million. The platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help cancer patients navigate diagnosis and treatment decisions.